中
About
Our Mission & Vision
Team
Leadership
Board of Directors
Scientific Advisory Board
Milestones
Pipeline
Ophthalmology
Neurology & Psychiatry
Partnership
Business Development
Our Partners
Newsroom
Press Releases
In The News
Media Room
Careers
Value & Behaviors
Benefits
Open Positions
Contact
About
Our Mission & Vision
Team
Milestones
Pipeline
Ophthalmology
Neurology & Psychiatry
Partnership
Business Development
Our Partners
Newsroom
Press Releases
In The News
Media Room
Careers
Value & Behaviors
Benefits
Open Positions
Contact
中
News
Press Releases
In The News
Media Room
May 25,2023
25
May 2023
AffaMed Therapeutics Announces Partner Allgenesis Reports Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial for the Treatment of Diabetic Macular Edema
Apr 17,2023
17
April 2023
AffaMed Therapeutics Announces Approval to Initiate a Phase 3 Registrational Clinical Trial in Mainland China for DEXTENZA
®
for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery
Apr 06,2023
06
April 2023
AffaMed Digital Announces Enrollment of First Patient in China Clinical Trial Investigating its Experimental Digital Therapeutic AMD201 for the Treatment of Post-stroke Cognitive Impairment
Mar 20,2023
20
March 2023
AffaMed Technologies Announces TFDA Approval of MINI WELL, MINI WELL PROXA, MINI WELL TORIC and MINI 4 Ready IOLs for Cataract Treatment in Taiwan
Mar 03,2023
03
March 2023
AffaMed Technologies Announces the First Implantation in the China Registrational Clinical Trial of MINI WELL
®
, the Progressive Extended Depth-of-Focus IOL
<<
<
1
2
3
4
5
6
7
>
>>
上一页
下一页
